PhiloGene

Philogen is a clinical-stage biotechnology company dedicated to the discovery and development of novel biopharmaceuticals for the treatment of cancer and chronic inflammatory diseases. The company specializes in the use of high-affinity ligands, such as human monoclonal antibodies or small organic molecules, to deliver bioactive payloads like cytokines or drugs specifically to the site of disease. Philogen's proprietary technology engine includes massive DNA-encoded chemical libraries and antibody phage display libraries, which facilitate the rapid identification of binders to disease-associated targets. Its lead clinical programs, Nidlegy and Fibromun, are currently in Phase 3 trials for oncology indications, positioning the company as a leader in the field of targeted immunocytokines.